10.6084/m9.figshare.4771195.v1
Gernez Y.
Gernez
Y.
Tirouvanziam R.
Tirouvanziam
R.
Yu G.
Yu
G.
Ghosn E.E.B.
Ghosn
E.E.B.
Reshamwala N.
Reshamwala
N.
Nguyen T.
Nguyen
T.
Tsai M.
Tsai
M.
Galli S.J.
Galli
S.J.
Herzenberg L.A.
Herzenberg
L.A.
Nadeau K.C.
Nadeau
K.C.
Supplementary Material for: Basophil CD203c Levels Are Increased at Baseline and Can Be Used to Monitor Omalizumab Treatment in Subjects with Nut Allergy
Karger Publishers
2017
Anaphylaxis
Atopic
CD203c
Cockroach allergen
Flow cytometry
Human basophils
Omalizumab
Peanut allergy
Tree nut allergy
2017-03-21 13:43:23
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Basophil_CD203c_Levels_Are_Increased_at_Baseline_and_Can_Be_Used_to_Monitor_Omalizumab_Treatment_in_Subjects_with_Nut_Allergy/4771195
<p><i>Rationale:</i> Basophils contribute to anaphylaxis and allergies.
We examined the utility of assessing basophil-associated surface
antigens (CD11b/CD63/CD123/CD203c/CD294) in characterizing and
monitoring subjects with nut allergy. <i>Methods:</i> We used flow
cytometry to analyze basophils at baseline (without any activation) and
after ex vivo stimulation of whole blood by addition of nut or other
allergens for 2, 10, and 30 min. We also evaluated whether basophil
expression of CD11b/CD63/CD123/CD203c/CD294 was altered in subjects
treated with anti-IgE monoclonal antibody (omalizumab) to reduce plasma
levels of IgE. <i>Results:</i> We demonstrate that basophil CD203c
levels are increased at baseline in subjects with nut allergy compared
to healthy controls (13 subjects in each group, p < 0.0001).
Furthermore, we confirm that significantly increased expression of
CD203c occurs on subject basophils when stimulated with the allergen to
which the subject is sensitive and can be detected rapidly (10 min of
stimulation, n = 11, p < 0.0008). In 5 subjects with severe peanut
allergy, basophil CD203c expression following stimulation with peanut
allergen was significantly decreased (p < 0.05) after 4 and 8 weeks
of omalizumab treatment but returned toward pretreatment levels after
treatment cessation. <i>Conclusions:</i> Subjects with nut allergy show
an increase of basophil CD203c levels at baseline and following rapid ex
vivo stimulation with nut allergen. Both can be reduced by omalizumab
therapy. These results highlight the potential of using basophil CD203c
levels for baseline diagnosis and therapeutic monitoring in subjects
with nut allergy.</p>